Brief: Regenxbio Inc - Phase Iib/Iii Trial To Be Initiated For Diabetic Retinopathy
07/08/2025 13:37
Aug 7 (Reuters) - Regenxbio Inc RGNX.O: REGENXBIO INC - PHASE IIB/III TRIAL TO BE INITIATED FOR DIABETIC RETINOPATHY REGENXBIO INC - TO RECEIVE $100 MILLION UPON FIRST SUBJECT DOSED REGENXBIO INC - ABBVIE TO FUND PHASE III ACHIEVE TRIAL IN WET AMD Source text: ID:nPn94zsGwa Further company coverage: RGNX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics